Physical Medicine & Rehabilitation Doctors in Lake Mary, FL Accepting Medicare

7 Physical Medicine & Rehabilitation doctors found. Showing 1 - 7

Nilusha Tania Fernando, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 325 Waymont Ct Ste 111, Lake Mary, FL 32746 Phone: 407-936-3345

Bella Bui, PTA Physical Medicine & Rehabilitation - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Waymont Ct Ste 120, Lake Mary, FL 32746 Phone: 407-323-0399

Dr. Luis A Gandara, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 701 Platinum Pt, Lake Mary, FL 32746 Phone: 407-206-4500    Fax: 407-643-2802

Christen Painter, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 925 Williston Park Pt # Pf, Lake Mary, FL 32746 Phone: 407-732-6926

Mrs. Alyssa Riddle, Physical Medicine & Rehabilitation - Neuromuscular Medicine Medicare: Not Enrolled in Medicare Practice Location: 934 Williston Park Pt Ste 1020, Lake Mary, FL 32746 Phone: 407-829-7311

Dr. Edwin Manuel Villalobos, M.D. Physical Medicine & Rehabilitation - Pain Medicine Medicare: Medicare Enrolled Practice Location: 2692 W Lake Mary Blvd, Lake Mary, FL 32746 Phone: 321-710-8027    Fax: 407-333-9974

Dr. Quyen Van Truong, MD Physical Medicine & Rehabilitation - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 761 Stirling Center Pl, Lake Mary, FL 32746 Phone: 386-274-2977

News Archive

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.

Psychologists must be educated to treat sexual minority youth

President Obama officially declared June as Lesbian, Gay, Bisexual and Transgender (LGBT) Pride Month. However, despite advances in civil rights, sexual minority youth are still at greater risk for suicide than their heterosexual peers, according to the Suicide Prevention Resource Center.

Screening smokers with community-acquired pneumonia could facilitate early diagnosis of lung cancer

Lung cancer is the leading cause of cancer mortality in the United States, with a five-year survival rate of just 17 percent. Smoking causes approximately 85 percent of all lung cancer cases, only 15 percent of which are diagnosed at an early stage. Most efforts to obtain early diagnosis have been unsuccessful, largely due to the highly aggressive nature of the disease.

Read more Medical News

› Verified 8 days ago